Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -5,032 | -6,067 | -6,739 | -5,458 | -1,750 |
| Depreciation Amortization | 439 | 343 | 103 | N/A | N/A |
| Accounts receivable | N/A | N/A | N/A | N/A | 1 |
| Accounts payable and accrued liabilities | -72 | 338 | N/A | N/A | N/A |
| Other Working Capital | 259 | 626 | -1,120 | -182 | 644 |
| Other Operating Activity | -216 | 197 | 1,509 | 1,460 | 293 |
| Operating Cash Flow | $-4,622 | $-4,564 | $-6,247 | $-4,180 | $-812 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -256 | -604 | -953 | N/A | N/A |
| Purchase Sale Intangibles | N/A | N/A | -212 | -178 | N/A |
| Other Investing Activity | 0 | 0 | -212 | -178 | 0 |
| Investing Cash Flow | $-256 | $-604 | $-1,164 | $-178 | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | 488 | 100 |
| Debt Repayment | N/A | N/A | -150 | -341 | N/A |
| Common Stock Issued | 2,783 | 5,915 | 1,873 | 13,654 | 520 |
| Other Financing Activity | 4,304 | -108 | -75 | -112 | 194 |
| Financing Cash Flow | $7,088 | $5,807 | $1,648 | $13,689 | $813 |
| Beginning Cash Position | 4,229 | 3,589 | 9,353 | 22 | 18 |
| End Cash Position | 6,439 | 4,229 | 3,589 | 9,353 | 22 |
| Net Cash Flow | $2,210 | $640 | $-5,763 | $9,331 | $4 |
| Free Cash Flow | |||||
| Operating Cash Flow | -4,622 | -4,564 | -6,247 | -4,180 | -812 |
| Capital Expenditure | -256 | -604 | -953 | N/A | N/A |
| Free Cash Flow | -4,878 | -5,168 | -7,200 | -4,180 | -812 |